Alexander A Brescia1, G Michael Deeb1,2, Stephane Leung Wai Sang2,3, Daizo Tanaka2,4, P Michael Grossman5,6, Devraj Sukul5,6, Chang He2, Patricia F Theurer2, Melissa Clark2, Francis L Shannon2,7, Stanley J Chetcuti5,6, Shinichi Fukuhara1,2. 1. Department of Cardiac Surgery (A.A.B., G.M.D., S.F.), University of Michigan, Ann Arbor. 2. Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor (G.M.D., S.L.W.S., D.T., C.H., P.F.T., M.C., F.L.S., S.F.). 3. Spectrum Health Medical Group, Cardiothoracic Surgery, Grand Rapids, MI (S.L.W.S.). 4. Henry Ford Hospital Division of Cardiac Surgery, Detroit, MI (D.T.). 5. Department of Internal Medicine (P.M.G., D.S., S.J.C.), University of Michigan, Ann Arbor. 6. Blue Cross Blue Shield Cardiovascular Consortium, Ann Arbor, MI (P.M.G., D.S., S.J.C.). 7. Division of Cardiovascular Surgery, Beaumont Health, Royal Oak, MI (F.L.S.).
Abstract
BACKGROUND: Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) since its initial approval in 2011, the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly understood. METHODS: Patients undergoing TAVR-explant between January 2012 and June 2020 at 33 hospitals in Michigan were identified in the Society of Thoracic Surgeons Database and linked to index TAVR data from the Transcatheter Valve Therapy Registry through a statewide quality collaborative. The primary outcome was operative mortality. Indications for TAVR-explant, contraindications to redo TAVR, operative data, and outcomes were collected from Society of Thoracic Surgeons and Transcatheter Valve Therapy databases. Baseline Society of Thoracic Surgeons Predicted Risk of Mortality was compared between index TAVR and TAVR-explant. RESULTS: Twenty-four surgeons at 12 hospitals performed TAVR-explants in 46 patients (median age, 73). The frequency of TAVR-explant was 0.4%, and the number of explants increased annually. Median time to TAVR-explant was 139 days and among known device types explanted, most were self-expanding valves (29/41, 71%). Common indications for TAVR-explant were procedure-related failure (35%), paravalvular leak (28%), and need for other cardiac surgery (26%). Contraindications to redo TAVR included need for other cardiac surgery (28%), unsuitable noncoronary anatomy (13%), coronary obstruction (11%), and endocarditis (11%). Overall, 65% (30/46) of patients underwent concomitant procedures, including aortic repair/replacement in 33% (n=15), mitral surgery in 22% (n=10), and coronary artery bypass grafting in 16% (n=7). The median Society of Thoracic Surgeons Predicted Risk of Mortality was 4.2% at index TAVR and 9.3% at TAVR-explant (P=0.001). Operative mortality was 20% (9/46) and 76% (35/46) of patients had in-hospital complications. Of patients alive at discharge, 37% (17/37) were discharged home and overall 3-month survival was 73±14%. CONCLUSIONS: TAVR-explant is rare but increasing, and its clinical impact is substantial. As the utilization of TAVR expands into younger and lower-risk patients, providers should consider the potential for future TAVR-explant during selection of an initial valve strategy.
BACKGROUND: Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) since its initial approval in 2011, the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly understood. METHODS: Patients undergoing TAVR-explant between January 2012 and June 2020 at 33 hospitals in Michigan were identified in the Society of Thoracic Surgeons Database and linked to index TAVR data from the Transcatheter Valve Therapy Registry through a statewide quality collaborative. The primary outcome was operative mortality. Indications for TAVR-explant, contraindications to redo TAVR, operative data, and outcomes were collected from Society of Thoracic Surgeons and Transcatheter Valve Therapy databases. Baseline Society of Thoracic Surgeons Predicted Risk of Mortality was compared between index TAVR and TAVR-explant. RESULTS: Twenty-four surgeons at 12 hospitals performed TAVR-explants in 46 patients (median age, 73). The frequency of TAVR-explant was 0.4%, and the number of explants increased annually. Median time to TAVR-explant was 139 days and among known device types explanted, most were self-expanding valves (29/41, 71%). Common indications for TAVR-explant were procedure-related failure (35%), paravalvular leak (28%), and need for other cardiac surgery (26%). Contraindications to redo TAVR included need for other cardiac surgery (28%), unsuitable noncoronary anatomy (13%), coronary obstruction (11%), and endocarditis (11%). Overall, 65% (30/46) of patients underwent concomitant procedures, including aortic repair/replacement in 33% (n=15), mitral surgery in 22% (n=10), and coronary artery bypass grafting in 16% (n=7). The median Society of Thoracic Surgeons Predicted Risk of Mortality was 4.2% at index TAVR and 9.3% at TAVR-explant (P=0.001). Operative mortality was 20% (9/46) and 76% (35/46) of patients had in-hospital complications. Of patients alive at discharge, 37% (17/37) were discharged home and overall 3-month survival was 73±14%. CONCLUSIONS: TAVR-explant is rare but increasing, and its clinical impact is substantial. As the utilization of TAVR expands into younger and lower-risk patients, providers should consider the potential for future TAVR-explant during selection of an initial valve strategy.
Authors: Uri Landes; John G Webb; Ole De Backer; Lars Sondergaard; Mohamed Abdel-Wahab; Lisa Crusius; Won-Keun Kim; Christian Hamm; Nicola Buzzatti; Matteo Montorfano; Sebastian Ludwig; Niklas Schofer; Lisa Voigtlaender; Mayra Guerrero; Abdallah El Sabbagh; Josep Rodés-Cabau; Leonardo Guimaraes; Ran Kornowski; Pablo Codner; Taishi Okuno; Thomas Pilgrim; Claudia Fiorina; Antonio Colombo; Antonio Mangieri; Helene Eltchaninoff; Luis Nombela-Franco; Maarten P H Van Wiechen; Nicolas M Van Mieghem; Didier Tchétché; Wolfgang H Schoels; Matthias Kullmer; Corrado Tamburino; Jan-Malte Sinning; Baravan Al-Kassou; Gidon Y Perlman; Haim Danenberg; Alfonso Ielasi; Chiara Fraccaro; Giuseppe Tarantini; Federico De Marco; Guy Witberg; Simon R Redwood; John C Lisko; Vasilis C Babaliaros; Mika Laine; Roberto Nerla; Fausto Castriota; Ariel Finkelstein; Itamar Loewenstein; Amnon Eitan; Ronen Jaffe; Philipp Ruile; Franz J Neumann; Nicolo Piazza; Hind Alosaimi; Horst Sievert; Kolja Sievert; Marco Russo; Martin Andreas; Matjaz Bunc; Azeem Latib; Rebecca Govdfrey; David Hildick-Smith; Janarthanan Sathananthan; Mark Hensey; Abdullah Alkhodair; Philipp Blanke; Jonathon Leipsic; David A Wood; Tamim M Nazif; Susheel Kodali; Martin B Leon; Marco Barbanti Journal: J Am Coll Cardiol Date: 2020-04-28 Impact factor: 24.094
Authors: Gilbert H L Tang; Syed Zaid; Eisha Gupta; Hasan Ahmad; Asaad Khan; Jason C Kovacic; Steven L Lansman; George D Dangas; Samin K Sharma; Annapoorna Kini Journal: JACC Cardiovasc Interv Date: 2019-07-08 Impact factor: 11.195
Authors: Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Luis Nombela-Franco; Henrique Barbosa Ribeiro; Marina Urena; Ricardo Allende; Ignacio Amat-Santos; Robert DeLarochellière; Eric Dumont; Daniel Doyle; Hugo DeLarochellière; Jerôme Laflamme; Louis Laflamme; Eulogio García; Carlos Macaya; Pilar Jiménez-Quevedo; Mélanie Côté; Sebastien Bergeron; Jonathan Beaudoin; Philippe Pibarot; Josep Rodés-Cabau Journal: J Am Coll Cardiol Date: 2014-03-26 Impact factor: 24.094
Authors: Nahoko Kato; Ratnasari Padang; Cristina Pislaru; William R Miranda; Mizuho Hoshina; Kentaro Shibayama; Hiroyuki Watanabe; Christopher G Scott; Kevin L Greason; Sorin V Pislaru; Vuyisile T Nkomo; Patricia A Pellikka Journal: Circulation Date: 2019-10-07 Impact factor: 29.690
Authors: Oliver K Jawitz; Brian C Gulack; Maria V Grau-Sepulveda; Roland A Matsouaka; Michael J Mack; David R Holmes; John D Carroll; Vinod H Thourani; J Matthew Brennan Journal: JACC Cardiovasc Interv Date: 2020-06-10 Impact factor: 11.195
Authors: Michael P Thompson; Alexander A Brescia; Hechuan Hou; Francis D Pagani; Devraj Sukul; Justin B Dimick; Donald S Likosky Journal: JAMA Cardiol Date: 2020-06-01 Impact factor: 14.676